Secondary Logo

Journal Logo

Current World Literature

doi: 10.1097/MOU.0b013e32835bb149
CURRENT WORLD LITERATURE: Bibliography
Free

This bibliography is compiled by clinicians from the relevant journals scanned by this publication. It is based on the literature regularly pulled into our database from OvidSP (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

▪ Papers considered by the reviewers to be of special interest

▪▪ Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline

Benign prostatic hyperplasia

Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

Review: (pp. 2–4)

Kopp RP, Freedland SJ, Parsons JK. Associations of Benign Prostatic Hyperplasia With Prostate Cancer: The Debate Continues. Eur Urol 2011; 60:699–700.

Kopp RP, Han M, Partin AW, Humphreys E, et al. Obesity and prostate enlargement in men with localized prostate cancer. BJU Int 2011; 108:1750–1755.

Korstanje C, Krauwinkel W, van Doesum-Wolters FLC. Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity? Br J Clin Pharmacol 2011; 72:218–225.

▪▪. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60:4550. [02]

Lepor H, Kazzazi A, Djavan B. alpha-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 2012; 22:7–15.

Li B, Gao WS, Dong CJ, Han XM, et al. Long-term safety, tolerability, and efficacy of alpha 1-adrenergic blocker in young men with primary bladder neck obstruction: Results from a single centre in China. Int Urol Nephrol 2012; 44:711–716.

▪▪. Orsted DD, Bojesen SE, Nielsen SF, et al. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 2011; 60:691. [08]

Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Reply from Authors re: Ryan P. Kopp, Stephen J. Freedland, J. Kellogg Parsons. Associations of Benign Prostatic Hyperplasia With Prostate Cancer: The Debate Continues. Eur Urol 2011; 60:699–700Eur Urol 2011; 60:701–702.

Pettaway CA, Lamerato LE, Eaddy MT, Edwards JK, et al. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int 2011; 108:1302–1308.

Russo A, Hedlund P, Montorsi F. Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy. Eur Urol Suppl 2011; 10:445–450.

▪. Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173:1419. [17]

Schenk JM, Kristal AR, White E, Neuhouser ML, et al. Re: “Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial” (vol 173, pg 1419, 2011). Am J Epidemiol 2011; 174:1425.

Srigley JR, De lahunt B, Evans AJ. Therapy-associated effects in the prostate gland. Histopathology 2012; 60:153–165.

Wilt TJ, Howe RW, Rutks I, MacDonald R. Terazosin for benign prostatic hyperplasia - art. no. CD003851. Cochrane Database Syst Rev 2011; 3851.

Wilt TJ, MacDonald R, Rutks I. Tamsulosin for benign prostatic hyperplasia - art. no. CD002081. Cochrane Database Syst Rev 2011; 2081.

Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 2011; 6:161–172.

Yu HJ, Lin ATL, Yang SSD, Tsui KH, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011; 108:1843–1848.

Zhou Y, Sun PH, Liu YW, Zhao X, et al. Safety and Pharmacokinetic Studies of Silodosin, a New alpha(1A)-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects. Biol Pharm Bull 2011; 34:1240–1245.

Back to Top | Article Outline

Correlation between benign prostatic hyperplasia and inflammation

Review: (pp. 5–10)

▪▪. Descazeaud A, Weinbreck N, Robert G, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. 108(2 Pt 2)2011: E23–E28. [39]

Gabuev A, Oelke M. Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH). Aktuelle Urol 2011; 42:167–178.

Lamb AD, Qadan M, Roberts S, Timlin H, et al. CD4(+) and CD8(+) T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia. BJU Int 2011; 108:E43–E50.

Lu Z, Gao Y, Tan AH, Yang XB, et al. Increased high-sensitivity c-reactive protein predicts a high risk of lower urinary tract symptoms in chinese male: Results from the fangchenggang area male health and examination survey. Prostate 2012; 72:193–200.

Macoska JA. Chemokines and BPH/LUTS. Differentiation 2011; 82:253–260.

Mandal S, Patil SB, Goel A. Re: Liao et al.: Serum C-reactive Protein Levels are Associated With Residual Urgency Symptoms in Patients With Benign Prostatic Hyperplasia After Medical Treatment. (Urology 2011;78:1373–1379). Urology 2012; 79:1192.

McLaren ID, Jerde TJ, Bushman W. Role of interleukins, IGF and stem cells in BPH. Differentiation 2011; 82:237–243.

Mehta V, Vezina CM. Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia. Differentiation 2011; 82:211–219.

Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82:184–199.

Ricke WA, Macoska JA, Cunha GR. Developmental, Cellular and Molecular Biology of Benign Prostatic Hyperplasia. Differentiation 2011; 82:165–167.

Robert G, Smit F, Hessels D, Jannink S, et al. Biomarkers for the Diagnosis of Prostatic Inflammation in Benign Prostatic Hyperplasia. Prostate 2011; 71:1701–1709.

Scarpa RM, Cracco CM. Serum C-reactive Protein Levels are Associated With Residual Urgency Symptoms in Patients With Benign Prostatic Hyperplasia After Medical Treatment EDITORIAL COMMENT. Urology 2011; 78:1378–1379.

Schauer IG, Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011; 82: 200–210.

▪. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171:571–582. [29]

▪▪. Sutcliffe S, Grubb Iii RL, Platz EA, et al. Nonsteroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2012; 110:1050–1059. [49]

Wang ZW, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 2011; 82:261–271.

Wu ZL, Yuan Y, Geng H, Xia SJ. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 2012; 14:316–319.

Back to Top | Article Outline

Imaging in benign prostatic hyperplasia: what is new?

Review: (pp. 11–16)

▪. Bellinger AS, Elliott SP, Yang L, et al. Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. J Urol 2012; 187:1739–1746. [04]

▪. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793–1803. [03]

Qi J, Yu YJ, Huang T, Xu D, et al. Comparation of the predictive value between ultrasonography and urodynamics for the efficacy of transurethral resection of prostate in benign prostatic hyperplasia patients. Chin Med J 2012; 125: 1536–1541.

▪. Strope SA, Elliott SP, Saigal CS, et al. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology 2011; 78:3–9. [06]

Zhai L, Polascik TJ, Foo WC, Rosenzweig S, et al. Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol 2012; 38:50–61.

Back to Top | Article Outline

Hormonal manipulation of benign prostatic hyperplasia

Review: (pp. 17–24)

A phosphodiesterase type 5 inhibitor for the treatment of benign prostatic hyperplasia, Formulary 2012; 47:3.

Altavilla D, Bitto A, Polito F, Irrera N, et al. The Combination of Serenoa Repens, Selenium and Lycopene is More Effective Than Serenoa Repens Alone to Prevent Hormone Dependent Prostatic Growth. J Urol 2011; 186:1524–1529.

Arias-Santiago S, Arrabal-Polo MA, Buendia-Eisman A, Arrabal-Martin M, et al. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. J Am Acad Dermatol 2012; 66:401–408.

▪. Aubry S, Aubert G, Cresteil T, Crich D. Synthesis and biological investigation of the β-thiolactone and β-lactam analogs of tetrahydrolipstatin. Org Biomol Chem 2012; 10:2629–2632. [51]

Barry MJ, Meleth S, Lee JY, Kreder KJ, et al. Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms A Randomized Trial. JAMA-J Am Med Assoc 2011; 306:1344–1351.

▪▪. Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int 2012; 109:731–738. [33]

Descazeaud A, Weinbreck N, Robert G, Vacherot F, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int 2011; 108:E23–E28.

Duborija-Kovacevic N, Jakovljevic V, Sabo A, Tomic Z, et al. Tolerability and toxicity of lipidosterolic extract of american dwarf palm Serenoa repens in Wistar rats: well-known extract, new insight. Eur Rev Med Pharmacol Sci 2011; 15:1311–1317.

Gabuev A, Oelke M. Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH). Aktuelle Urol 2011; 42:167–178.

Gacci M, Corona G, Salvi M, Vignozzi L, et al. A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with alpha-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol 2012; 61:994–1003.

▪. Garrido M, Bratoeff E, Bonilla D, et al. New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor. J Steroid Biochem Mol Biol 2011; 127:367–373. [52]

Gu X, Strom K, Spaliviero M, Wong C. Does age affect the efficacy and safety of GreenLight HPS (TM) laser photoselective vaporization prostatectomy? Aging Male 2012; 15:63–67.

Iglesias-Gato D, Carsten T, Vesterlund M, Pousette A, et al. Androgen-independent Effects of Serenoa repens Extract (Prostasan (R)) on Prostatic Epithelial Cell Proliferation and Inflammation. Phytother Res 2012; 26:259–264.

Johansen TEB, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int 2012; 109:731–738.

Kaplan SA. Re: Mortality Trends for Benign Prostatic Hyperplasia and Prostate Cancer in English Populations 1979–2006 Editorial Comment. J Urol 2011; 186:2332.

Kaplan SA. Re: Relationship Between Lower Urinary Tract Symptoms and Serum Levels of Sex Hormones in Men With Symptomatic Benign Prostatic Hyperplasia Editorial Comment. J Urol 2011; 186:1983–1984.

Kawashima H, Nakatani T. Involvement of estrogen receptors in prostatic diseases. Int J Urol 2012; 19:512–522.

Kim MK, Zhao C, Kim SD, Kim DG, et al. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male 2012; 15:90–95.

Kim WT, Choi YD, Park C, Kim YW, et al. Parathyroid Hormone Is Not Involved in Prostate Growth in Patients With Benign Prostatic Hyperplasia. Prostate 2011; 71:1210–1215.

Kumar R, Verma V, Sarswat A, Maikhuri JP, et al. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms-action of two new agents. Invest New Drugs 2012; 30:582–593.

Lee SH, Oh CY, Park KK, Chung MS, et al. Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. Asian J Androl 2011; 13:728–731.

Liao CH, Li HY, Chung SD, Chiang HS, et al. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years. Aging Male 2012; 15:28–33.

Liatsikos E, Kyriazis I, Kallidonis P, Stolzenburg JU. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options. Aging Male 2011; 14:141–149.

▪▪. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2012; 109:1162–1169. [42]

▪. Montorsi F, Roehrborn C, Garcia-penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) s. BJU Int 2011; 107:1426–1431. [31]

Na YQ, Ye ZQ, Zhang SZ. Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension. Clin Drug Invest 2012; 32:29–39.

Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia 2012; 44:396–409.

▪▪. Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108:388–394. [29]

Nickel JC, Gilling P, Tammela TL, Morrill B, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108:388–394.

Niu YN, Ge RB, Hu LB, Diaz C, et al. Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue and Implications for BPH Therapy. Prostate 2011; 71:1317–1324.

Rawson DJ, Ballard S, Barber C, Barker L, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem 2012; 20:498–509.

▪. Rick FG, Schally AV, Block NL, et al. LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71:736–747. [13]

▪▪. Rick FG, Schally AV, Block NL, et al. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108:3755–3760. [14]

Rick FG, Szalontay L, Schally AV, Block NL, et al. Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage. J Urol 2012; 187:1498–1504.

▪. Rick FG, Szalontay L, Schally AV, et al. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 2012; 187:1498–1504. [15]

▪. Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin. BJU Int 2011; 107:946–954. [32]

▪. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol 2012; 187:1732–1738. [23]

Sengupta G, Hazra A, Kundu A, Ghosh A. Comparison of Murraya koenigii- and Tribulus terrestris-Based Oral Formulation Versus Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Men Aged > 50 Years: A Double-Blind, Double-Dummy, Randomized Controlled Trial. Clin Ther 2011; 33:1943–1952.

Sun J, Xiang H, Yang LL, Chen JB. A Review on Steroidal 5 alpha-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia. Curr Med Chem 2011; 18:3576–3589.

van der Sluis TM, Meuleman EJH, van Moorselaar RJA, Bui HN, et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU Int 2012; 109:183–188.

van der Sluis TM, Vis AN, van Moorselaar RJA, Bui HN, et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU Int 2012; 109:176–182.

Wang HH, Hsieh CJ, Lin KJ, Chu SH, et al. Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males. Asian J Surg 2011; 34:163–167.

Wu ZL, Yuan Y, Geng H, Xia SJ. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 2012; 14:316–319.

Zong HT, Peng XX, Yang CC, Zhang Y. A systematic review of the effects and mechanisms of preoperative 5 alpha-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Asian J Androl 2011; 13:812–818.

Back to Top | Article Outline

New emerging technologies in benign prostatic hyperplasia

Review: (pp. 25–29)

Biester K, Skipka G, Jahn R, Buchberger B, et al. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority). BJU Int 2012; 109:722–730.

Brisinda G, Vanella S, Marniga G, Crocco A, et al. Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin. Curr Med Chem 2011; 18:3468–3475.

Brunken C, Seitz C, Tauber S, Schmidt R. Transurethral GreenLight Laser Enucleation of the Prostate-A Feasibility Study. J Endourol 2011; 25:1199–1201.

Bruyere F. Photoselective vaporization of the prostate. Prog Urol 2011; 21:808–810.

Bruyere F, Huglo D, Challacombe B, Haillot O, et al. Blood Loss Comparison During Transurethral Resection of Prostate and High Power GreenLight (TM) Laser Therapy Using Isotopic Measure of Red Blood Cells Volume. J Endourol 2011; 25:1655–1659.

Capitan C, Blazquez C, Martin MD, Hernandez V, et al. GreenLight HPS 120-W Laser Vaporization versus Transurethral Resection of the Prostate for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized Clinical Trial with 2-year Follow-up. Eur Urol 2011; 60:734–739.

▪▪. Chartier-Kastler E, Mehnert U, Denys P, et al. Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 2011; 21:13–21. [10]

▪. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012; 79:5–11. [07]

Cho MC, Park JH, Jeong MS, Yi JS, et al. Predictor of De Novo Urinary Incontinence Following Holmium Laser Enucleation of the Prostate. Neurourol Urodyn 2011; 30:1343–1349.

Chung DE, Wysock JS, Lee RK, Melamed SR, et al. Outcomes and Complications After 532 nm Laser Prostatectomy in Anticoagulated Patients With Benign Prostatic Hyperplasia. J Urol 2011; 186:977–981.

Crawford ED, Hirst K, Kusek JW, Donnell RF, et al. Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial. J Urol 2011; 186:965–970.

de la Torre G, Barusso G, Chernobilsky V, Borghi M, et al. Outpatient Simultaneous Treatment of Benign Prostatic Hyperplasia and Bladder Lithiasis with GreenLight (TM) and Holmium Laser. J Endourol 2012; 26:164–167.

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association. Prog Urol 2012; 22:73–79.

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of benign prostatic hyperplasia by thermotherapy and other emerging techniques: A review of the literature by the LUTS committee of the French Urological Association. Prog Urol 2012; 22:87–92.

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of BPH by laser therapies: A review of the literature by the LUTS committee of the French urological association. Prog Urol 2012; 22:80–86.

Descazeaud A, Weinbreck N, Robert G, Vacherot F, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int 2011; 108:E23–E28.

Djavan B, Kazzazi A, Bostanci Y. Revival of thermotherapy for benign prostatic hyperplasia. Curr Opin Urol 2012; 22:16–21.

Elhilali M. Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia Comment. J Endourol 2012; 26:524.

Elmansy HM, Kotb A, Elhilali MM. Holmium Laser Enucleation of the Prostate: Long-Term Durability of Clinical Outcomes and Complication Rates During 10 Years of Followup. J Urol 2011; 186:1972–1976.

Elmansy HM, Kotb A, Elhilali MM. Is There a Way to Predict Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate? J Urol 2011; 186:1977–1981.

Fayad AS, El Sheikh MG, Zakaria T, Elfottoh HA, et al. Holmium Laser Enucleation Versus Bipolar Resection of the Prostate: A Prospective Randomized Study. Which to Choose? J Endourol 2011; 25:1347–1352.

Fournier G, Perrouin-Verbe MA, Papin G, Deruelle C. Usefulness of real time transrectal ultrasonography to monitor the Greenlight XPS (R) (180W) laser prostatectomy. Prog Urol 2011; 21:383–386.

Gilling PJ, Wilson LC, King CJ, Westenberg AM, et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 2012; 109:408–411.

Gu X, Vricella GJ, Spaliviero M, Wong C. Does Size Really Matter? The Impact of Prostate Volume on the Efficacy and Safety of GreenLight HPS (TM) Laser Photoselective Vaporization of the Prostate. J Endourol 2012; 26:525–530.

Hall SA, Chiu GR, Kaufman DW, Wittert GA, et al. Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey. BJU Int 2012; 109:1676–1684.

▪. Hempel CR, Hall TL, Cain CA, et al. Histotripsy fractionation of prostate tissue: local effects and systemic response in a canine model. J Urol 2011; 185:1484–1489. [23]

Kaplan SA. Re: Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia Editorial Comment. J Urol 2012; 187:212–213.

Kelly DC, Das A. Holmium laser enucleation of the prostate technique for benign prostatic hyperplasia. Can J Urol 2012; 19:6131–6134.

Kim CS, Song HY, Jeong IG, Yeo HJ, et al. Temporary Placement of Covered Retrievable Expandable Nitinol Stents with Barbs in High-risk Surgical Patients with Benign Prostatic Hyperplasia: Work in Progress. J Vasc Interv Radiol 2011; 22:1420–1426.

Ko WJ, Choi BB, Kang HW, Rajabhandharaks D, et al. Defining Optimal Laser-Fiber Sweeping Angle for Effective Tissue Vaporization Using 180W 532 nm Lithium Triborate Laser. J Endourol 2012; 26:313–317.

▪. Kotsar A, Nieminen R, Isotalo T, et al. Preclinical evaluation of new indomethacin-eluting biodegradable urethral stent. J Endourol 2012; 26:387–392. [05]

Le Gal S, Le Toquin-Bernard S, Hurel S, Doerfler A, et al. Treatment of benign prostatic hyperplasia by Prostiva (R): About a series of 76 cases. Prog Urol 2011; 21:417–425.

Lee NG, Xue H, Lerner LB. Trends and attitudes in surgical management of benign prostatic hyperplasia. Can J Urol 2012; 19:6170–6175.

Liao NK, Yu JJ. Transurethral Bipolar Plasmakinetic Resection Combined with 2 mu m Continuous Wave Laser Vaporization: A New Method for the Treatment of Large Volume Benign Prostatic Hyperplasia. Photomed Laser Surg 2012; 30:320–324.

Liatsikos E, Kyriazis I, Kallidonis P, Sakellaropoulos G, et al. Photoselective GreenLight (TM) Laser Vaporization Versus Transurethral Resection of the Prostate in Greece: A Comparative Cost Analysis. J Endourol 2012; 26:168–173.

Liatsikos E, Kyriazis I, Kallidonis P, Stolzenburg JU. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options. Aging Male 2011; 14:141–149.

Lovvik A, Yaqub S, Oustad H, Sand TE, et al. Can noninvasive evaluation of benign prostatic obstruction be optimized? Curr Opin Urol 2012; 22:1–6.

Luo GH, Xia SJ, Sun ZL. In vitro comparison of the vaporesection of human benign prostatic hyperplasia using 70-and 120-W 2-mu m lasers. Asian J Androl 2011; 13:636–639.

▪. Malaeb BS, Yu X, McBean AM, et al. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology 2012; 79:1111–1116. [02]

Malde S, Rajagopalan A, Koslowski M, Simoes AD, et al. Potassium-Titanyl-Phosphate Laser Vaporization of the Prostate: A Case Series of an Unusual Complication. J Endourol 2012; 26:682–685.

Mangera A, Andersson KE, Apostolidis A, Chapple C, et al. Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol 2011; 60:784–795.

Marchal C, Perez JE, Herrera B, Machuca FJ, et al. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012; 31:86–92.

Ozturk MI, Kalkan S, Koca O, Gunes M, et al. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia 2012; 44:791–795.

Protogerou V, Kostakopoulos A. Laparoscopic treatment of benign prostatic hyperplasia (bph): overview of current techniques. do our patients need it? BJU Int 2011; 108:E8.

Quan CY, Chang WL, Chen J, Li B, et al. Laparoscopic Madigan Prostatectomy. J Endourol 2011; 25:1879–1882.

Rosenthal BD, Di Trolio JV. Photoselective vaporization of the prostate in office and outpatient settings. Can J Urol 2012; 19:6223–6226.

▪▪. Sertcelik MN, Bozkurt IH, Yalcinkaya F, et al. Long-term results of permanent urethral stent Memotherm implantation in the management of recurrent bulbar urethral stenosis. BJU Int 2011; 108:1839–1842. [04]

Sharib J, Truntzer J, Young J, Jordan G, et al. Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia. J Endourol 2012; 26:520–523.

▪. Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2011; 2:377–383. [18]

▪▪. Silva J, Pinto R, Carvalho T, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 2011; 107:1950–1954. [17]

Stief CG. Using Laser to Unobstruct the Obstructed Prostatic Urethra Due to Benign Prostatic Hyperplasia: Has Transurethral Resection of the Prostate Finally Become History, or Is It Here to Stay? Eur Urol 2011; 60:740–741.

Strope SA, Yang L, Nepple KG, Andriole GL, et al. Population Based Comparative Effectiveness of Transurethral Resection of the Prostate and Laser Therapy for Benign Prostatic Hyperplasia. J Urol 2012; 187:1341–1345.

Tasci AI, Ilbey YO, Luleci H, Cicekler O, et al. 120-W GreenLight Laser Photoselective Vaporization of Prostate for Benign Prostatic Hyperplasia: Midterm Outcomes. Urology 2011; 78:134–140.

Tasci AI, Sahin S, Tugcu V, Ilbey YO, et al. 120-W GreenLight Laser Photoselective Vaporization of Prostate for Benign Prostatic Hyperplasia: Midterm Outcomes REPLY. Urology 2011; 78:141.

Tubaro A, De Nunzio C. Re: Safety and Feasibility of the Prostatic Urethral Lift: A Novel, Minimally Invasive Treatment for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). Eur Urol 2011; 60:1120–1121.

Voigt S, Huttig F, Koch R, Propping S, et al. Risk Factors for Incidental Prostate Cancer-Who Should not Undergo Vaporization of the Prostate for Benign Prostate Hyperplasia? Prostate 2011; 71:1325–1331.

Vora A, Mittal S, Hwang J, Bandi G. Robot-Assisted Simple Prostatectomy: Multi-Institutional Outcomes for Glands Larger Than 100 Grams. J Endourol 2012; 26:499–502.

Wang Y, Liu ZS, Yu JN, Ding YL, et al. Efficacy of electroacupuncture at Zhongliao point (BL33) for mild and moderate benign prostatic hyperplasia: study protocol for a randomized controlled trial - art. no. 211. Trials 2011; 12:26.

Woldrich JM, Palazzi-Churas K, Lakin C, Albo M, et al. Prostate laser vaporization in men with urinary retention. BJU Int 2011; 108:395–398.

Woo HH. Photoselective vaporization of the prostate using the 120-W lithium triborate laser in enlarged prostates (>120 cc). BJU Int 2011; 108:860–863.

Woo HH, Bolton DM, Laborde E, Jack G, et al. Preservation of Sexual Function with the Prostatic Urethral Lift: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Sex Med 2012; 9:568–575.

Yip SK, Chan NH, Chiu P, Lee KW, et al. A Randomized Controlled Trial Comparing the Efficacy of Hybrid Bipolar Transurethral Vaporization and Resection of the Prostate with Bipolar Transurethral Resection of the Prostate. J Endourol 2011; 25:1889–1894.

Yu JS, Shen KH, Chen WC, Her JS, et al. Effects of Electroacupuncture on Benign Prostate Hyperplasia Patients with Lower Urinary Tract Symptoms: A Single-Blinded, Randomized Controlled Trial. Evid-based Complement Altern Med 2011.

Zhao ZG, Ma WJ, Xuan XJ, Ou LL, et al. Impact of Plasmakinetic Enucleation of the Prostate (PKEP) on Sexual Function: Results of a Prospective Trial. J Sex Med 2012; 9:1473–1481.

Zhu GB, Xie CY, Wang XH, Tang XQ. Bipolar Plasmakinetic Transurethral Resection of Prostate in 132 Consecutive Patients With Large Gland: Three-year Follow-up Results. Urology 2012; 79:397–402.

Zorn KC, Liberman D. GreenLight 180W XPS photovaporization of the prostate: how I do it. Can J Urol 2011; 18:5918–5926.

Back to Top | Article Outline

Bladder outlet procedures in the setting of anticoagulation therapy

Review: (pp. 30–37)

Biester K, Skipka G, Jahn R, Buchberger B, et al. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non-inferiority). BJU Int 2012; 109:722–730.

Brisinda G, Vanella S, Marniga G, Crocco A, et al. Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin. Curr Med Chem 2011; 18:3468–3475.

Brunken C, Seitz C, Tauber S, Schmidt R. Transurethral GreenLight Laser Enucleation of the Prostate-A Feasibility Study. J Endourol 2011; 25:1199–1201.

Bruyere F. Photoselective vaporization of the prostate. Prog Urol 2011; 21:808–810.

Bruyere F, Huglo D, Challacombe B, Haillot O, et al. Blood Loss Comparison During Transurethral Resection of Prostate and High Power GreenLight (TM) Laser Therapy Using Isotopic Measure of Red Blood Cells Volume. J Endourol 2011; 25:1655–1659.

Capitan C, Blazquez C, Martin MD, Hernandez V, et al. GreenLight HPS 120-W Laser Vaporization versus Transurethral Resection of the Prostate for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized Clinical Trial with 2-year Follow-up. Eur Urol 2011; 60:734–739.

Cho MC, Park JH, Jeong MS, Yi JS, et al. Predictor of De Novo Urinary Incontinence Following Holmium Laser Enucleation of the Prostate. Neurourol Urodyn 2011; 30:1343–1349.

▪. Chung DE, Wysock JS, Lee RK, et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 2011; 186:977–981. [23]

Chung DE, Wysock JS, Lee RK, Melamed SR, et al. Outcomes and Complications After 532 nm Laser Prostatectomy in Anticoagulated Patients With Benign Prostatic Hyperplasia. J Urol 2011; 186:977–981.

Crawford ED, Hirst K, Kusek JW, Donnell RF, et al. Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial. J Urol 2011; 186:965–970.

de la Torre G, Barusso G, Chernobilsky V, Borghi M, et al. Outpatient Simultaneous Treatment of Benign Prostatic Hyperplasia and Bladder Lithiasis with GreenLight (TM) and Holmium Laser. J Endourol 2012; 26:164–167.

▪. Delongchamps NB, Robert G, de la Taille A, et al. Surgical management of BPH in patients on oral anticoagulation: transurethral bipolar plasma vaporization in saline versus transurethral monopolar resection of the prostate. Can J Urol 2011; 18:6007–6012. [27]

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association. Prog Urol 2012; 22:73–79.

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of benign prostatic hyperplasia by thermotherapy and other emerging techniques: A review of the literature by the LUTS committee of the French Urological Association. Prog Urol 2012; 22:87–92.

Delongchamps NB, Robert G, Descazeaud A, Cornu JN, et al. Surgical management of BPH by laser therapies: A review of the literature by the LUTS committee of the French urological association. Prog Urol 2012; 22:80–86.

▪. Descazeaud A, Robert G, Lebdai S, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 2011; 29:211–216. [11]

Djavan B, Kazzazi A, Bostanci Y. Revival of thermotherapy for benign prostatic hyperplasia. Curr Opin Urol 2012; 22:16–21.

Elhilali M. Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia Comment. J Endourol 2012; 26:524.

Elmansy HM, Kotb A, Elhilali MM. Holmium Laser Enucleation of the Prostate: Long-Term Durability of Clinical Outcomes and Complication Rates During 10 Years of Followup. J Urol 2011; 186:1972–1976.

Elmansy HM, Kotb A, Elhilali MM. Is There a Way to Predict Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate? J Urol 2011; 186:1977–1981.

Fan X, Haney CR, Agrawal G, Pelizzari CA, et al. High-Resolution MRI of Excised Human Prostate Specimens Acquired with 9.4T in Detection and Identification of Cancers: Validation of a Technique. J Magn Reson Imaging 2011; 34:956–961.

Fayad AS, El Sheikh MG, Zakaria T, Elfottoh HA, et al. Holmium Laser Enucleation Versus Bipolar Resection of the Prostate: A Prospective Randomized Study. Which to Choose? J Endourol 2011; 25:1347–1352.

Fournier G, Perrouin-Verbe MA, Papin G, Deruelle C. Usefulness of real time transrectal ultrasonography to monitor the Greenlight XPS (R) (180W) laser prostatectomy. Prog Urol 2011; 21:383–386.

Gabuev A, Oelke M. Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH). Aktuelle Urol 2011; 42:167–178.

Gilling PJ, Wilson LC, King CJ, Westenberg AM, et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 2012; 109:408–411.

Gu X, Strom K, Spaliviero M, Wong C. Does age affect the efficacy and safety of GreenLight HPS (TM) laser photoselective vaporization prostatectomy? Aging Male 2012; 15:63–67.

Gu X, Vricella GJ, Spaliviero M, Wong C. Does Size Really Matter? The Impact of Prostate Volume on the Efficacy and Safety of GreenLight HPS (TM) Laser Photoselective Vaporization of the Prostate. J Endourol 2012; 26:525–530.

Kaplan SA. Re: Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia Editorial Comment. J Urol 2012; 187:212–213.

Kelly DC, Das A. Holmium laser enucleation of the prostate technique for benign prostatic hyperplasia. Can J Urol 2012; 19:6131–6134.

Kim CS, Song HY, Jeong IG, Yeo HJ, et al. Temporary Placement of Covered Retrievable Expandable Nitinol Stents with Barbs in High-risk Surgical Patients with Benign Prostatic Hyperplasia: Work in Progress. J Vasc Interv Radiol 2011; 22:1420–1426.

Ko WJ, Choi BB, Kang HW, Rajabhandharaks D, et al. Defining Optimal Laser-Fiber Sweeping Angle for Effective Tissue Vaporization Using 180W 532 nm Lithium Triborate Laser. J Endourol 2012; 26:313–317.

Le Gal S, Le Toquin-Bernard S, Hurel S, Doerfler A, et al. Treatment of benign prostatic hyperplasia by Prostiva (R): About a series of 76 cases. Prog Urol 2011; 21:417–425.

Lee NG, Xue H, Lerner LB. Trends and attitudes in surgical management of benign prostatic hyperplasia. Can J Urol 2012; 19:6170–6175.

Liao NK, Yu JJ. Transurethral Bipolar Plasmakinetic Resection Combined with 2 mu m Continuous Wave Laser Vaporization: A New Method for the Treatment of Large Volume Benign Prostatic Hyperplasia. Photomed Laser Surg 2012; 30:320–324.

Liatsikos E, Kyriazis I, Kallidonis P, Sakellaropoulos G, et al. Photoselective GreenLight (TM) Laser Vaporization Versus Transurethral Resection of the Prostate in Greece: A Comparative Cost Analysis. J Endourol 2012; 26:168–173.

Liatsikos E, Kyriazis I, Kallidonis P, Stolzenburg JU. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options. Aging Male 2011; 14:141–149.

Lovvik A, Yaqub S, Oustad H, Sand TE, et al. Can noninvasive evaluation of benign prostatic obstruction be optimized? Curr Opin Urol 2012; 22:1–6.

Luo GH, Xia SJ, Sun ZL. In vitro comparison of the vaporesection of human benign prostatic hyperplasia using 70-and 120-W 2-mu m lasers. Asian J Androl 2011; 13:636–639.

Malde S, Rajagopalan A, Koslowski M, Simoes AD, et al. Potassium-Titanyl-Phosphate Laser Vaporization of the Prostate: A Case Series of an Unusual Complication. J Endourol 2012; 26:682–685.

Mangera A, Andersson KE, Apostolidis A, Chapple C, et al. Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol 2011; 60:784–795.

Marchal C, Perez JE, Herrera B, Machuca FJ, et al. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012; 31:86–92.

▪. Michielsen DP, Coomans D, Van Lersberghe C, Braeckman JG. Comparison of the haemostatic properties of conventional monopolar and bipolar transurethral resection of the prostate in patients on oral anticoagulants. Arch Med Sci 2011; 7:858–863. [37]

Ozturk MI, Kalkan S, Koca O, Gunes M, et al. Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia 2012; 44:791–795.

Protogerou V, Kostakopoulos A. Laparoscopic treatment of benign prostatic hyperplasia (bph): overview of current techniques. do our patients need it? BJU Int 2011; 108:E8.

Quan CY, Chang WL, Chen J, Li B, et al. Laparoscopic Madigan Prostatectomy. J Endourol 2011; 25:1879–1882.

▪. Raj MD, McDonald C, Brooks AJ, et al. Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. Urology 2011; 78:1380–1384. [30]

Rosenthal BD, Di Trolio JV. Photoselective vaporization of the prostate in office and outpatient settings. Can J Urol 2012; 19:6223–6226.

Sharib J, Truntzer J, Young J, Jordan G, et al. Panurethral Stricture After Photovaporization of the Prostate for Benign Prostatic Hyperplasia. J Endourol 2012; 26:520–523.

▪. Spernat DM, Hossack TA, Woo HH. Photoselective vaporization of the prostate in men taking clopidogrel. Urol Ann 2011; 3:93–95. [26]

Stief CG. Using Laser to Unobstruct the Obstructed Prostatic Urethra Due to Benign Prostatic Hyperplasia: Has Transurethral Resection of the Prostate Finally Become History, or Is It Here to Stay? Eur Urol 2011; 60:740–741.

Strope SA, Yang L, Nepple KG, Andriole GL, et al. Population Based Comparative Effectiveness of Transurethral Resection of the Prostate and Laser Therapy for Benign Prostatic Hyperplasia. J Urol 2012; 187:1341–1345.

Tasci AI, Ilbey YO, Luleci H, Cicekler O, et al. 120-W GreenLight Laser Photoselective Vaporization of Prostate for Benign Prostatic Hyperplasia: Midterm Outcomes. Urology 2011; 78:134–140.

Tasci AI, Sahin S, Tugcu V, Ilbey YO, et al. 120-W GreenLight Laser Photoselective Vaporization of Prostate for Benign Prostatic Hyperplasia: Midterm Outcomes REPLY. Urology 2011; 78:141.

▪. Taylor K, Filgate R, Guo DY, Macneil F. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int. 108(Suppl. 2)2011:45–50. [24]

Tubaro A, De Nunzio C. Re: Safety and Feasibility of the Prostatic Urethral Lift: A Novel, Minimally Invasive Treatment for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). Eur Urol 2011; 60:1120–1121.

Vaughan CP, Johnson TM, Goode PS, Redden DT, et al. Vitamin D and Lower Urinary Tract Symptoms Among US Men: Results from the 2005–2006 National Health and Nutrition Examination Survey. Urology 2011; 78:1292–1297.

Voigt S, Huttig F, Koch R, Propping S, et al. Risk Factors for Incidental Prostate Cancer-Who Should not Undergo Vaporization of the Prostate for Benign Prostate Hyperplasia? Prostate 2011; 71:1325–1331.

Vora A, Mittal S, Hwang J, Bandi G. Robot-Assisted Simple Prostatectomy: Multi-Institutional Outcomes for Glands Larger Than 100 Grams. J Endourol 2012; 26:499–502.

Wang Y, Liu ZS, Yu JN, Ding YL, et al. Efficacy of electroacupuncture at Zhongliao point (BL33) for mild and moderate benign prostatic hyperplasia: study protocol for a randomized controlled trial - art. no. 211. Trials 2011; 12:26.

Woldrich JM, Palazzi-Churas K, Lakin C, Albo M, et al. Prostate laser vaporization in men with urinary retention. BJU Int 2011; 108:395–398.

Woo HH. Photoselective vaporization of the prostate using the 120-W lithium triborate laser in enlarged prostates (>120 cc). BJU Int 2011; 108:860–863.

Woo HH, Bolton DM, Laborde E, Jack G, et al. Preservation of Sexual Function with the Prostatic Urethral Lift: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Sex Med 2012; 9:568–575.

Yip SK, Chan NH, Chiu P, Lee KW, et al. A Randomized Controlled Trial Comparing the Efficacy of Hybrid Bipolar Transurethral Vaporization and Resection of the Prostate with Bipolar Transurethral Resection of the Prostate. J Endourol 2011; 25:1889–1894.

Yu JS, Shen KH, Chen WC, Her JS, et al. Effects of Electroacupuncture on Benign Prostate Hyperplasia Patients with Lower Urinary Tract Symptoms: A Single-Blinded, Randomized Controlled Trial. Evid-based Complement Altern Med 2011.

Zhao ZG, Ma WJ, Xuan XJ, Ou LL, et al. Impact of Plasmakinetic Enucleation of the Prostate (PKEP) on Sexual Function: Results of a Prospective Trial. J Sex Med 2012; 9:1473–1481.

Zhu GB, Xie CY, Wang XH, Tang XQ. Bipolar Plasmakinetic Transurethral Resection of Prostate in 132 Consecutive Patients With Large Gland: Three-year Follow-up Results. Urology 2012; 79:397–402.

Zorn KC, Liberman D. GreenLight 180W XPS photovaporization of the prostate: how I do it. Can J Urol 2011; 18:5918–5926.

Back to Top | Article Outline

Nutrition and benign prostatic hyperplasia

Review: (pp. 38–41)

Amarenco G, Serikoff A, Chartier-Kastler E, Grise P, et al. Metabolic syndrome and urinary disorders. Prog Urol 2012; 22:207–213.

▪. Barry MJ, Meleth S, Lee J, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011; 306:1344–1351. [03]

De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, et al. The Correlation Between Metabolic Syndrome and Prostatic Diseases. Eur Urol 2012; 61:560–570.

Fournier G, Perrouin-Verbe MA, Papin G, Deruelle C. Usefulness of real time transrectal ultrasonography to monitor the Greenlight XPS (R) (180W) laser prostatectomy. Prog Urol 2011; 21:383–386.

Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation 2011; 82:244–252.

Gabuev A, Oelke M. Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH). Aktuelle Urol 2011; 42:167–178.

Kim WT, Yun SJ, Choi YD, Kim GY, et al. Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels. J Korean Med Sci 2011; 26:1214–1218.

Lee M. Focus on Phosphodiesterase Inhibitors for the Treatment of Erectile Dysfunction in Older Men. Clin Ther 2011; 33:1590–1608.

Lee SH, Oh CY, Park KK, Chung MS, et al. Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. Asian J Androl 2011; 13:728–731.

▪. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of cernilton for the treatment of benign prostatic hyperplasia. BJU Int 2000; 85:836–841. [04]

Nicolau C, Bunesch L, Peri L, Salvador R, et al. Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. Br J Radiol 2011; 84:1091–1099.

Nishimune A, Yoshiki H, Uwada J, Anisuzzaman ASM, et al. Phenotype pharmacology of lower urinary tract alpha(1)-adrenoceptors. Br J Pharmacol 2012; 165:1226–1234.

Parsons JK, Messer K, White M, Barrett-Connor E, et al. Obesity Increases and Physical Activity Decreases Lower Urinary Tract Symptom Risk in Older Men: The Osteoporotic Fractures in Men Study. Eur Urol 2011; 60:1173–1180.

Penson DF, Munro HM, Signorello LB, Blot WJ, et al. Obesity, Physical Activity and Lower Urinary Tract Symptoms: Results From the Southern Community Cohort Study. J Urol 2011; 186:2316–2322.

Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, et al. Diabetes Treatment and Progression of Benign Prostatic Hyperplasia in Community-dwelling Black and White Men. Urology 2012; 79:102–108.

▪▪. Schwarz S, Obermüller-Jevic UC, Hellmis E, et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008; 138:49–53. [09]

St Sauver JL, Sarma AV, Hollingsworth JM, Jacobson DJ, et al. Associations Between Modest Weight Changes and Onset and Progression of Lower Urinary Tract Symptoms in Two Population-based Cohorts. Urology 2011; 78:437–441.

Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 2011; 72:197–204.

Ventura S. What makes the alpha 1A-adrenoceptor gene express the alpha 1L-adrenoceptor functional phenotype? Br J Pharmacol 2012; 165:1223–1225.

Wang HH, Hsieh CJ, Lin KJ, Chu SH, et al. Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males. Asian J Surg 2011; 34:163–167.

Wehrberger C, Temml C, Gutjahr G, Berger I, et al. Is There an Association Between Lower Urinary Tract Symptoms and Cardiovascular Risk in Men? A Cross Sectional and Longitudinal Analysis. Urology 2011; 78:1063.

Wright JL, Lin DW, Stanford JL. The Effect of Demographic and Clinical Factors on the Relationship Between BMI and PSA Levels. Prostate 2011; 71:1631–1637.

Yamada S, Ito Y, Tsukada H. alpha(1)-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. Br J Clin Pharmacol 2011; 72:205–217.

Back to Top | Article Outline

BPH science

Aweimer A, Stachon T, Tannapfel A, Koller M, et al. Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH. Prostate Cancer Prostatic Dis 2012; 15:157–164.

Berry PA, Birnie R, Droop AP, Maitland NJ, et al. The Calcium Sensor STIM1 Is Regulated by Androgens in Prostate Stromal Cells. Prostate 2011; 71:1646–1655.

Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, et al. Acute bacterial inflammation of the mouse prostate. Prostate 2012; 72:307–317.

Chan CK, Yip SKH, Wu IPH, Li ML, et al. Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms. BJU Int 2012; 109:1690–1696.

Chen IH, Tong YC, Cheng JT. Metabolic syndrome decreases tissue perfusion and induces glandular hyperplasia in the fructose-fed rat prostate. Neurourol Urodyn 2012; 31:600–604.

Chittur S, Parr B, Marcovici G. Inhibition of Inflammatory Gene Expression in Keratinocytes Using a Composition Containing Carnitine, Thioctic Acid and Saw Palmetto Extract. Evid-based Complement Altern Med 2011.

Cunha GR, Ricke WA. A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation 2011; 82:168–172.

De Nunzio C, Ahyai S, Autorino R, Bachmann A, et al. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: Research Priorities. Eur Urol 2011; 60:1205–1206.

Descazeaud A, Weinbreck N, Robert G, Vacherot F, et al. Transforming growth factor beta-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int 2011; 108:E23–E28.

Dey A, Lang RJ, Exintaris B. Nitric Oxide Signaling Pathways Involved in the Inhibition of Spontaneous Activity in the Guinea Pig Prostate. J Urol 2012; 187:2254–2260.

Dhingra N, Bhardwaj TR, Mehta N, Mukhopadhyay T, et al. 17-Oximino-5-androsten-3 beta-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level. Med Chem Res 2011; 20:817–825.

Ejike C, Ezeanyika LUS. Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing telfairia occidentalis seeds. Afr J Tradit Complement Alt M 2011; 8:398–404.

Gonzales C, Leiva-Revilla J, Rubio J, Gasco M, et al. Effect of red maca (Lepidium meyenii) on prostate zinc levels in rats with testosterone-induced prostatic hyperplasia. Andrologia 2012; 44:362–369.

Gratzke C, Pahde A, Dickmann M, Reich O, et al. Predictive factors for urinary retention following kidney transplantation in male patients. Scand J Urol Nephrol 2012; 46:44–47.

Haga N, Aikawa K, Ishibashi K, Yanagida T, et al. Long-term administration of prazosin improves bladder storage function: Results from a study in spontaneously hypertensive rats. Int J Urol 2011; 18:785–791.

Hayashi T, Kondo T, Ishimatsu M, Takeya M, et al. Function and expression pattern of TRPM8 in bladder afferent neurons associated with bladder outlet obstruction in rats. Auton Neurosci-Basic Clin 2011; 164:27–33.

Jiang M, Strand DW, Franco OE, Clark PE, et al. PPAR gamma: A molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation 2011; 82:220–236.

Jin LH, Andersson KE, Han JU, Kwon YH, et al. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol-Regul Integr Comp Physiol 2011; 301:R896–R904.

Kawashima H, Nakatani T. Involvement of estrogen receptors in prostatic diseases. Int J Urol 2012; 19:512–522.

Kumar R, Verma V, Sarswat A, Maikhuri JP, et al. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms-action of two new agents. Invest New Drugs 2012; 30:582–593.

Kumazaki M, Ando H, Ushijima K, Maekawa T, et al. Influence of Dosing Time on the Efficacy and Safety of Finasteride in Rats. J Pharmacol Exp Ther 2011; 338:718–723.

Lamb AD, Qadan M, Roberts S, Timlin H, et al. CD4(+) and CD8(+) T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia. BJU Int 2011; 108:E43–E50.

Macoska JA. Chemokines and BPH/LUTS. Differentiation 2011; 82:253–260.

Maiga A, Mouriera G, Quinton L, Rouget C, et al. G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon 2012; 59: 487–496.

McLaren ID, Jerde TJ, Bushman W. Role of interleukins, IGF and stem cells in BPH. Differentiation 2011; 82:237–243.

Mehta V, Vezina CM. Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia. Differentiation 2011; 82:211–219.

Mori F, Tanigawa K, Endo K, Minamiguchi K, et al. VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia. Prostate 2011; 71:1579–1586.

Nahata A, Dixit VK. Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats. Andrologia 2012; 44:160–174.

Nahata A, Dixit VK. Sphaeranthus indicus Attenuates Testosterone induced Prostatic Hypertrophy in Albino Rats. Phytother Res 2011; 25:1839–1848.

Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82:184–199.

Niwa S, Ohya S, Kojima Y, Sasaki S, et al. Down-Regulation of the Large-Conductance Ca2+-Activated K+ Channel, K(Ca)1.1 in the Prostatic Stromal Cells of Benign Prostate Hyperplasia. Biol Pharm Bull 2012; 35:737–744.

Ohya S, Niwa S, Kojima Y, Sasaki S, et al. Intermediate-Conductance Ca2+-Activated K+ Channel, K(Ca)3.1, as a Novel Therapeutic Target for Benign Prostatic Hyperplasia. J Pharmacol Exp Ther 2011; 338:528–536.

Ozgur-Akdemir A, Demirturk K, Karabakan M, Volkan-Oztekin C, et al. Imatinib Mesylate (Gleevec) as Protein-tyrosine Kinase Inhibitor Elicits Smooth Muscle Relaxation in Isolated Human Prostatic Tissue - art. no. 968.e1. Urology 2011; 78:E1.

Pinsky MR, Gur S, Tracey AJ, Harbin A, et al. The Effects of Chronic 5-Alpha-Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function. J Sex Med 2011; 8:3066–3074.

Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, et al. Longitudinal Changes of Benign Prostate-specific Antigen and. Urology 2012; 79:655–661.

Ricke WA, Macoska JA, Cunha GR. Developmental, Cellular and Molecular Biology of Benign Prostatic Hyperplasia. Differentiation 2011; 82:165–167.

Sato S, Hatanaka T, Yuyama H, Ukai M, et al. Tamsulosin Potently and Selectively Antagonizes Human Recombinant alpha(1A/1D)-Adrenoceptors: Slow Dissociation from the alpha(1A)-Adrenoceptor May Account for Selectivity for alpha(1A)-Adrenoceptor over alpha(1B)-Adrenoceptor Subtype. Biol Pharm Bull 2012; 35:72–77.

Schauer IG, Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011; 82:200–210.

Shin IS, Lee MY, Jung DY, Seo CS, et al. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia. Food Chem Toxicol 2012; 50:884–888.

Sun F, Sanchez FM, Crisostomo V, Diaz-Guemes I, et al. Transarterial Prostatic Embolization: Initial Experience in a Canine Model. Am J Roentgenol 2011; 197:495–501.

Tokmadzic VS, Tomas MI, Sotosek S, Laskarin G, et al. Different Perforin Expression in Peripheral Blood and Prostate Tissue in Patients with Benign Prostatic Hyperplasia and Prostate Cancer. Scand J Immunol 2011; 74:368–376.

White CW, Short JL, Haynes JM, Matsui M, et al. Contractions of the Mouse Prostate Elicited by Acetylcholine Are Mediated by M-3 Muscarinic Receptors. J Pharmacol Exp Ther 2011; 339:870–877.

Zhang MG, Wu W, Zhang CM, Wang XJ, et al. Effects of Oral Finasteride on Erectile Function in a Rat Model. J Sex Med 2012; 9:1328–1336.

Zhang XH, Zang N, Wei Y, Yin J, et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol-Endocrinol Metab 2012; 302:E243–E253.

Zhou Y, Sun PH, Liu YW, Zhao X, et al. Safety and Pharmacokinetic Studies of Silodosin, a New alpha(1A)-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects. Biol Pharm Bull 2011; 34:1240–1245.

Back to Top | Article Outline

Robotics

MRI–ultrasound fusion for guidance of targeted prostate biopsy

Review: (pp. 43–50)

▪▪. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22:746–757. [08]

▪. Barzell WE, Melamed MR, Cathcart P, et al. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 2012; 188:762–767. [31]

▪▪. Hoeks CM, Schouten MG, Bomers JG, et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012 [Epub ahead of print]. [09]

▪. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261:46–66. [12]

▪▪. Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2012 [Epub ahead of print]. [10]

▪▪. Natarajan S, Marks LS, Margolis DJ, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol 2011; 29:334–342. [22]

▪▪. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281–1285. [18]

▪▪. Sonn GA, Natarajan S, Margolis DJA, et al. Targeted biopsy in the detection of prostate cancer using an office-based MR-US fusion device. J Urol (in press). [24]

▪▪. Ukimura O, Desai MM, Palmer S, et al. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol 2012; 187:1080–1086. [21]

Back to Top | Article Outline

Robotic retroperitoneal surgery: a contemporary review

Review: (pp. 51–56)

Benway BM, Bhayani SB. Surgical outcomes of robot-assisted partial nephrectomy. BJU Int 2011; 108:955–961.

Cadeddu JA. Re: Robot-Assisted Laparoendoscopic Single-Site Surgery: Partial Nephrectomy for Renal Malignancy Editorial Comment. J Urol 2011; 186:1276–1277.

Cadeddu JA. Zero Ischemia'' Partial Nephrectomy: Novel Laparoscopic and Robotic Technique Editorial Comment. J Urol 2011; 186:77.

Cha EK, Lee DJ, Del Pizzo JJ. Current status of robotic partial nephrectomy (RPN). BJU Int 2011; 108:935–941.

Dasgupta P. Robotic partial nephrectomy in the setting of prior abdominal surgery editorial comment. BJU Int 2011; 108:419.

Ficarra V, Bhayani S, Porter J, Buffi N, et al. Predictors of Warm Ischemia Time and Perioperative Complications in a Multicenter, International Series of Robot-Assisted Partial Nephrectomy. Eur Urol 2012; 61:395–402.

Francisco IFS, Sweeney MC, Wagner AA. Robot-Assisted Partial Nephrectomy: Early Unclamping Technique. J Endourol 2011; 25:305–308.

Ghani KR, Anderson C. Closing the deal: renorrhaphy during laparoscopic and robotic partial nephrectomy. BJU Int 2011; 108:2–4.

Kaouk JH, Spana G, Hillyer SP, White MA, et al. Robotic-Assisted Laparoscopic Partial Nephrectomy for a 7-cm Mass in a Renal Allograft. Am J Transplant 2011; 11:2242–2246.

Long JA, Yakoubi R, Lee B, Guillotreau J, et al. Robotic Versus Laparoscopic Partial Nephrectomy for Complex Tumors: Comparison of Perioperative Outcomes. Eur Urol 2012; 61:1257–1262.

Mir SA, Cadeddu JA, Sleeper JP, Lotan Y. Cost Comparison of Robotic, Laparoscopic, and Open Partial Nephrectomy. J Endourol 2011; 25:447–453.

Mufarrij PW, Krane LS, Rajamahanty S, Hemal AK. Does Nephrometry Scoring of Renal Tumors Predict Outcomes in Patients Selected for Robot-Assisted Partial Nephrectomy? J Endourol 2011; 25:1649–1653.

Naeem N, Petros F, Sukumar S, Patel M, et al. Robot-Assisted Partial Nephrectomy in Obese Patients. J Endourol 2011; 25:101–105.

▪. Ng CS, Gill IS, Ramani AP, et al. Transperitoneal versus retroperitoneal laparoscopic partial nephrectomy: patient selection and perioperative outcomes. J Urol 2005; 174:846–849. [07]

Patil MB, Gill IS. Surgery Illustrated - Surgical Atlas Zero-ischaemia robotic and laparoscopic partial nephrectomy (PN). BJU Int 2011; 108:780–792.

Sammon J, Petros F, Sukumar S, Bhandari A, et al. Barbed Suture for Renorrhaphy During Robot-Assisted Partial Nephrectomy. J Endourol 2011; 25:529–533.

Savage SJ. Complications After Robotic Partial Nephrectomy at Centers of Excellence: Multi-Institutional Analysis of 450 Cases EDITORIAL COMMENT. J Urol 2011; 186:421–422.

Seo IY, Rim JS. Bilateral Robotic Single-Site Partial Nephrectomy. J Laparoendosc Adv Surg Tech 2011; 21:435–438.

Sukumar S, Rogers CG. Robot-Assisted Partial Nephrectomy. J Endourol 2011; 25:151–157.

Taneja SS. Multi-Institutional Analysis of Robotic Partial Nephrectomy for Hilar Versus Nonhilar Lesions in 446 Consecutive Cases - Editorial Comment. J Urol 2011; 185: 1638–1639.

Taneja SS. Re: ‘‘Zero Ischemia’' Partial Nephrectomy: Novel Laparoscopic and Robotic Technique Editorial Comment. J Urol 2011; 186:1803–1804.

Taneja SS. Renal Damage Caused by Warm Ischaemia During Laparoscopic and Robot-Assisted Partial Nephrectomy: An Assessment Using Tc 99m-DTPA Glomerular Filtration Rate Editorial Comment. J Urol 2011; 186:837–838.

Tobis S, Knopf J, Silvers C, Yao J, et al. Near Infrared Fluorescence Imaging With Robotic Assisted Laparoscopic Partial Nephrectomy: Initial Clinical Experience for Renal Cortical Tumors. J Urol 2011; 186:47–52.

Back to Top | Article Outline

Comparative effectiveness of minimally invasive versus open lymphadenectomy in urological cancers

Review: (pp. 57–64)

▪. Abaza R, Dangle PP, Gong MC, et al. Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an extended template. J Urol 2012; 187:1200–1204. [17]

▪▪. Abaza R, Lowe G. Feasibility and adequacy of robot-assisted lymphadenectomy for renal-cell carcinoma. J Endourol 2011; 25:1155–1159. [59]

▪. Abe T, Harabayashi T, Shinohara N, et al. Outcome of regional lymph node dissection in conjunction with laparoscopic nephroureterectomy for urothelial carcinoma of the upper urinary tract. J Endourol 2011; 25:803–807. [92]

Alloussi SH, Huber S, Gakis G, Stenzl A, et al. The Importance of Lymphadenectomy for Muscle Invasive Transitional Cell Carcinoma of the Human Bladder - A Review of the Literature. Aktuelle Urol 2011; 42:115–121.

Challacombe B. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons. BJU Int 2011; 108: 747–748.

Cost NG, Da Justa DG, Granberg CF, Cooksey RM, et al. Robot-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection in an Adolescent Population. J Endourol 2012; 26:635–640.

Davis JW, Shah JB, Achim M. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int 2011; 108:993–998.

▪. Gondo T, Yoshioka K, Nakagami Y, et al. Robotic versus open radical cystectomy: prospective comparison of perioperative and pathologic outcomes in Japan. Jpn J Clin Oncol 2012; 42:625–631. [38]

Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, et al. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 2011; 107:642–646.

▪. Hellenthal NJ, Hussain A, Andrews PE, et al. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 2011; 107:642–646. [42]

▪▪. Hu JC, Prasad SM, Gu X, et al. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology 2011; 77:402–406. [08]

▪. Kates M, Lavery HJ, Brajtbord J, et al. Decreasing rates of lymph node dissection during radical nephrectomy for renal cell carcinoma. Ann Surg Oncol 2012; 19:2693–2699. [52]

Lallas CD, Pe ML, Thumar AB, Chandrasekar T, et al. Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU Int 2011; 107:1136–1140.

▪▪. Lallas CD, Pe ML, Thumar AB, et al. Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU Int 2011; 107:1136–1140. [27]

Lavery HJ, Martinez-Suarez HJ, Abaza R. Robotic extended pelvic lymphadenectomy for bladder cancer with increased nodal yield. BJU Int 2011; 107:1802–1805.

▪. Mullins JK, Hyndman ME, Mettee LZ, Pavlovich CP. Comparison of extraperitoneal and transperitoneal pelvic lymph node dissection during minimally invasive radical prostatectomy. J Endourol 2011; 25:1883–1887. [30]

Mullins JK, Hyndman ME, Mettee LZ, Pavlovich CP. Comparison of Extraperitoneal and Transperitoneal Pelvic Lymph Node Dissection During Minimally Invasive Radical Prostatectomy. J Endourol 2011; 25:1883–1887.

Orvieto MA, Coelho RF, Chauhan S, Palmer KJ, et al. Incidence of lymphoceles after robot-assisted pelvic lymph node dissection. BJU Int 2011; 108:1185–1190.

Patel AR, Steinberg GD. Quality of Lymphadenectomy is Equivalent With Robotic and Open Cystectomy Using an Extended Template EDITORIAL COMMENT. J Urol 2012; 187:1204–1205.

▪. Richards KA, Kader AK, Otto R, et al. Is Robot-assisted radical cystectomy justified in the elderly? a comparison of robotic versus open radical cystectomy for bladder cancer in elderly ≥75 years old. J Endourol 2012; 26:1301–1306. [48]

▪▪. Roscigno M, Brausi M, Heidenreich A, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011; 60:776–783. [80]

Schwentner C, Todenhofer T, Mundhenk J, Horstmann M, et al. Robotic Laparoscopic Cystectomy: On the Way to a Standard Procedure? Aktuelle Urol 2011; 42:103–108.

Shah AD, Abaza R. Clinical Pathway for 3-Day Stay After Robot-Assisted Cystectomy. J Endourol 2011; 25:1253–1258.

Silberstein JL, Vickers AJ, Power NE, Parra RO, et al. Pelvic Lymph Node Dissection for Patients with Elevated Risk of Lymph Node Invasion During Radical Prostatectomy: Comparison of Open, Laparoscopic and Robot-Assisted Procedures. J Endourol 2012; 26:748–753.

Tobias-Machado M, Correa WF, Reis LO, Starling ES, et al. Single-Site Video Endoscopic Inguinal Lymphadenectomy: Initial Report. J Endourol 2011; 25:607–610.

▪. van der Poel HG, De Blok W, Tillier C, Van Muilekom E. Robot assisted laparoscopic prostatectomy (RALP): nodal dissection results during the first 440 cases in 2 surgeons. J Endourol 2012. [Epub ahead of print] [13]

▪▪. Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011; 185: 1615–1620. [56]

▪. Withrow DR, De Groot JM, Siemens DR, Groome PA. Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study. BJU Int 2011; 108:209–216. [23]

Back to Top | Article Outline

Tips and tricks to robot-assisted radical cystectomy and intracorporeal diversion

Review: (pp. 65–71)

Choudhury SM, Mahesan NM, Elhage O, Khan MS, et al. Oncological outcomes of robot-assisted radical cystectomy. BJU Int 2011; 108:1679.

Hosseini A, Adding C, Nilsson A, Jonsson MN, et al. Robotic cystectomy: surgical technique. BJU Int 2011; 108:962–968.

Jonsson MN, Adding LC, Hosseini A, Schumacher MC, et al. Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion in Patients with Transitional Cell Carcinoma of the Bladder. Eur Urol 2011; 60:1066–1073.

Lee R, Chughtai B, Herman M, Shariat SF, et al. Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. BJU Int 2011; 108:976–983.

Lee R, Ng CK, Shariat SF, Borkina A, et al. The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. BJU Int 2011; 108:1886–1892.

Lee SH, Chung MS, Chung YG, Park KK, et al. Does performance of robot-assisted laparoscopic radical prostatectomy within 2 weeks of prostate biopsy affect the outcome? Int J Urol 2011; 18:141–146.

Lima E, Branco F, Parente J, Autorino R, et al. Transvesical natural orifice transluminal endoscopic surgery (NOTES) nephrectomy with kidney morcellation: a proof of concept study. BJU Int 2012; 109:1533–1537.

Rehman J, Sangalli MN, Guru K, de Naeyer G, et al. Total intracorporeal robot-assisted laparoscopic ileal conduit (Bricker) urinary diversion: technique and outcomes. Can J Urol 2011; 18:5548–5556.

Richards KA, Kader K, Pettus JA, Smith JJ, et al. Does Initial Learning Curve Compromise Outcomes for Robot-Assisted Radical Cystectomy? A Critical Evaluation of the First 60 Cases While Establishing a Robotics Program. J Endourol 2011; 25:1553–1558.

Sano T, Nakashima M, Haitani T, Kajita Y, et al. Posterior musculofascial plate reconstruction promotes early restoration of continence and prevents severe incontinence in patients undergoing laparoscopic radical prostatectomy. Int J Urol 2012; 19:475–479.

Schwentner C, Todenhofer T, Mundhenk J, Horstmann M, et al. Robotic Laparoscopic Cystectomy: On the Way to a Standard Procedure? Aktuelle Urol 2011; 42:103–108.

Smith AB, Raynor M, Amling CL, Busby JE, et al. Multi-Institutional Analysis of Robotic Radical Cystectomy for Bladder Cancer: Perioperative Outcomes and Complications in 227 Patients. J Laparoendosc Adv Surg Tech 2012; 22:17–21.

▪. Styn NR, Montgomery JS, Wood DP, et al. Matched comparison of robotic-assisted and open radical cystectomy. Urology 2012; 79:1303–1309. [04]

Takenaka A, Tewari AK. Anatomical basis for carrying out a state-of-the-art radical prostatectomy. Int J Urol 2012; 19:7–19.

▪▪. Yu HY, Hevelone ND, Lipsitz SR, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol 2012; 61:1239–1244. [24]

▪▪. Yuh BE, Nazmy M, Ruel NH, et al. Standardized Analysis of Frequency and Severity of Complications After Robot-assisted Radical Cystectomy. Eur Urol 2012. [23]

Zehnder P, Gill IS. Cost-effectiveness of open versus laparoscopic versus robotic-assisted laparoscopic cystectomy and urinary diversion. Curr Opin Urol 2011; 21:415–419.

Back to Top | Article Outline

Current controversies in pediatric urologic robotic surgery

Review: (pp. 72–77)

Kim PH, Patil MB, Kim SS, Dorey F, et al. Early comparison of nephrectomy options in children (open, transperitoneal laparoscopic, laparo-endoscopic single site (LESS), and robotic surgery). BJU Int 2012; 109:910–915.

▪. Marchini GS, Hong YK, Minnillo BJ, et al. Robotic assisted laparoscopic ureteral reimplantation in children: case matched comparative study with open surgical approach. J Urol 2011; 185:1870–1875. [17]

▪▪. Minnillo BJ, Cruz JA, Sayao RH, et al. Long-term experience and outcomes of robotic assisted laparoscopic pyeloplasty in children and young adults. J Urol 2011; 185:1455–1460. [04]

O'Brien ST, Shukla AR. Transition from open to robotic-assisted pediatric pyeloplasty: A feasibility and outcome study. J Pediatr Urol 2012; 8:276–281.

▪. O'Brien ST, Shukla AR. Transition from open to robotic-assisted pediatric pyeloplasty: a feasibility and outcome study. J Pediatr Urol 2012; 8:276–281. [11]

▪▪. Rowe CK, Pierce MW, Tecci KC, et al. A comparative direct cost analysis of pediatric urologic robot-assisted laparoscopic surgery versus open surgery: could robot-assisted surgery be less expensive? J Endourol 2012; 26:871–877. [31]

Tomaszewski JJ, Casella DP, Turner RM, Casale P, et al. Pediatric Laparoscopic and Robot-Assisted Laparoscopic Surgery: Technical Considerations. J Endourol 2012; 26:602–613.

Back to Top | Article Outline

Anatomic and technical considerations for optimizing recovery of urinary function during robotic-assisted radical prostatectomy

Review: (pp. 78–87)

Badalato GM, Wosnitzer MS, Truesdale MD, Sandri M, et al. Evaluation of preoperative bioimpedance spectroscopy quantification of body composition on predicting postoperative outcomes following robotic assisted radical prostatectomy (RARP). Can J Urol 2011; 18:6031–6036.

Challacombe B. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons. BJU Int 2011; 108: 747–748.

▪. Choi WW, Freire MP, Soukup JR, et al. Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. World J Urol 2011; 29:21–27. [52]

Connolly SS, Cathcart PJ, Gilmore P, Kerger M, et al. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. BJU Int 2012; 109:752–759.

Dev H, Sharma NL, Dawson SN, Neal DE, et al. Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. BJU Int 2012; 109:1074–1080.

▪▪. Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012; 62:405–417. [45]

Gupta NP, Singh P, Nayyar R. Outcomes of robot-assisted radical prostatectomy in men with previous transurethral resection of prostate. BJU Int 2011; 108:1501–1505.

Hakimi AA, Faleck DM, Agalliu I, Rozenblit AM, et al. Preoperative and Intraoperative Measurements of Urethral Length as Predictors of Continence After Robot-Assisted Radical Prostatectomy. J Endourol 2011; 25:1025–1030.

Hakimi AA, Faleck DM, Sobey S, Ioffe E, et al. Assessment of complication and functional outcome reporting in the minimally invasive prostatectomy literature from 2006 to the present. BJU Int 2012; 109:26–30.

Huang AC, Kowalczyk KJ, Hevelone ND, Lipsitz SR, et al. The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes. Eur Urol 2011; 59:595–603.

▪. Hung AJ, Abreu AL, Shoji S, et al. Robotic transrectal ultrasonography during robot-assisted radical prostatectomy. Eur Urol 2012; 62:341–348. [25]

Hung CF, Yang CK, Cheng CL, Ou YC. Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. Anticancer Res 2011; 31:3497–3501.

▪. Hurtes X, Roupret M, Vaessen C, et al. Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU Int 2012; 110: 875–883. [42]

Jung JH, Lee JW, Arkoncel FRP, Cho NH, et al. Significance of Perineural Invasion, Lymphovascular Invasion, and High-Grade Prostatic Intraepithelial Neoplasia in Robot-Assisted Laparoscopic Radical Prostatectomy. Ann Surg Oncol 2011; 18:3828–3832.

Kasraeian A, Barret E, Chan J, Sanchez-Salas R, et al. Comparison of the rate, location and size of positive surgical margins after laparoscopic and robot-assisted laparoscopic radical prostatectomy. BJU Int 2011; 108: 1174–1178.

Kim SC, Song C, Kim W, Kang T, et al. Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. Eur Urol 2011; 60: 413–419.

Kim SC, Song C, Kim W, Kang T, et al. Reply from Authors re: Andrew Fuller, Stephen E. Pautler. Additional Evidence for Improved Functional Outcomes Following Robot-Assisted Radical Prostatectomy. Eur Urol 2011; 60: 420–421Eur Urol 2011; 60:421–422.

Ko YH, Coelho RF, Chauhan S, Sivaraman A, et al. Factors Affecting Return of Continence 3 Months After Robot-Assisted Radical Prostatectomy: Analysis From a Large, Prospective Data by a Single Surgeon. J Urol 2012; 187:190–194.

Koie T, Yamamoto H, Hatakeyama S, Kudoh S, et al. Minimum incision endoscopic radical prostatectomy: Clinical and oncological outcomes at a single institute. Ejso 2011; 37:805–810.

Kowalczyk KJ, Huang AC, Hevelone ND, Lipsitz SR, et al. Stepwise Approach for Nerve Sparing Without Countertraction During Robot-Assisted Radical Prostatectomy: Technique and Outcomes. Eur Urol 2011; 60:536–547.

Labanaris AP, Witt JH, Zugor V. Robotic-assisted Radical Prostatectomy in Men >= 75 Years of Age. Surgical, Oncological and Functional Outcomes. Anticancer Res 2012; 32:2085–2089.

Labanaris AP, Zugor V, Witt JH. Robotic-assisted Radical Prostatectomy in Men <= 150 Years of Age. Surgical, Oncological and Functional Outcomes. Anticancer Res 2012; 32:2097–2101.

Lee DI, Wedmid A, Mendoza P, Sharma S, et al. Bladder Neck Plication Stitch: A Novel Technique During Robot-Assisted Radical Prostatectomy to Improve Recovery of Urinary Continence. J Endourol 2011; 25:1873–1877.

▪. Lei Y, Alemozaffar M, Williams SB, et al. Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol 2011; 59:235–243. [17]

Louie-Johnsun M, Ouyang R, Indrajit B, Haque M. Laparoscopic radical prostatectomy: introduction of training during our first 50 cases. ANZ Journal of Surgery 2012; 82:131–135.

Madeb R, Golijanin D, Knopf JK, Kowalczyk J, et al. The Impact of Robotics on Treatment of Localized Prostate Cancer and Resident Education in Rochester, New York. J Endourol 2011; 25:573–577.

Magheli A, Gonzalgo ML, Su LM, Guzzo TJ, et al. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int 2011; 107:1956–1962.

McNicholas T. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons. BJU Int 2011; 108:747.

Meeks JJ, Eastham JA. Robotic Prostatectomy: The Rise of the Machines or Judgment Day. Eur Urol 2012; 61:686–687.

Mottrie A, Gallina A, De Wil P, Thuer D, et al. Balancing continence function and oncological outcomes during robot-assisted radical prostatectomy (RARP). BJU Int 2011; 108:999–1006.

Nilsson AE, Schumacher MC, Johansson E, Carlsson S, et al. Age at surgery, educational level and long-term urinary incontinence after radical prostatectomy. BJU Int 2011; 108:1572–1577.

Novara G. Factors Affecting Return of Continence 3 Months After Robot-Assisted Radical Prostatectomy: Analysis From a Large, Prospective Data by a Single Surgeon EDITORIAL COMMENT. J Urol 2012; 187:195.

Novara G, Ficarra V, D'Elia C, Secco S, et al. Trifecta outcomes after robot-assisted laparoscopic radical prostatectomy. BJU Int 2011; 107:100–104.

Ou YC, Yang CR, Wang J, Cheng CL, et al. Learning Curve of Robotic-assisted Radical Prostatectomy With 60 Initial Cases by a Single Surgeon. Asian J Surg 2011; 34:74–80.

Ou YC, Yang CR, Wang J, Yang CK, et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int 2011; 108:420–425.

Patel V, Re: A. Prospective, Non-Randomized Trial Comparing Robot-Assisted Laparoscopic and Retropubic Radical Prostatectomy in One European Institution. Eur Urol 2011; 60:599–600.

Patel VR, Coelho RF, Rocco B, Orvieto M, et al. Positive Surgical Margins After Robotic Assisted Radical Prostatectomy: A Multi-Institutional Study. J Urol 2011; 186:511–516.

Patel VR, Schatloff O, Chauhan S, Sivaraman A, et al. The Role of the Prostatic Vasculature as a Landmark for Nerve Sparing During Robot-Assisted Radical Prostatectomy. Eur Urol 2012; 61:571–576.

Patel VR, Sivaraman A, Coelho RF, Chauhan S, et al. Pentafecta: A New Concept for Reporting Outcomes of Robot-Assisted Laparoscopic Radical Prostatectomy. Eur Urol 2011; 59:702–707.

Peyromaure M. Re: Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. Eur Urol 2012; 61:220–221.

▪▪. Rocco B, Cozzi G, Spinelli MG, et al. Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature. Eur Urol 2012; 62:779–790. [43]

Schatloff O, Chauhan S, Sivaraman A, Kameh D, et al. Anatomic Grading of Nerve Sparing During Robot-Assisted Radical Prostatectomy. Eur Urol 2012; 61:796–802.

Skarecky D, Morales B, Chang A, Ahlering T. Simple Method to Predict Return of Continence After Robot-Assisted Radical Prostatectomy. J Endourol 2011; 25:1451–1455.

Srivastava A, Peyser A, Gruschow S, Harneja N, et al. Surgical strategies to promote early continence recovery after robotic radical prostatectomy. Arch Esp Urol 2012; 65:529–541.

Tan G, Srivastava A, Grover S, Peters D, et al. Optimizing Vesicourethral Anastomosis Healing After Robot-Assisted Laparoscopic Radical Prostatectomy: Lessons Learned from Three Techniques in 1900 Patients. J Endourol 2010; 24:1975–1983.

Tewari A, Grover S, Sooriakumaran P, Srivastava A, et al. Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int 2012; 109:596–602.

Tewari AK, Shevchuk MM, Sterling J, Grover S, et al. Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery. BJU Int 2011; 108:1421–1429.

Touijer K. Positive surgical margin rate, location, and size following laparoscopic versus robotic-assisted laparoscopic radical prostatectomy. BJU Int 2011; 108: 1178–1179.

▪▪. von Bodman C, Matsushita K, Savage C, et al. Recovery of urinary function after radical prostatectomy: predictors of urinary function on preoperative prostate magnetic resonance imaging. J Urol 2012; 187:945–950. [22]

Walsh PC. Re: Stepwise Approach for Nerve Sparing Without Countertraction During Robot-Assisted Radical Prostatectomy: Technique and Outcomes Editorial Comment. J Urol 2012; 187:500.

Willis DL, Gonzalgo ML, Brotzman M, Feng ZY, et al. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012; 109:898–905.

Zugor V, Labanaris AP, Bauer RM, Witt JH. Surgical and Oncological Outcomes in Patients with a Preoperative PSA Value < 4 ng/ml Undergoing Robot-assisted Radical Prostatectomy. Anticancer Res 2012; 32:2079–2083.

Zugor V, Witt JH, Heidenreich A, Porres D, et al. Surgical and Oncological Outcomes in Patients with Preoperative PSA > 20 ng/ml Undergoing Robot-assisted Radical Prostatectomy. Anticancer Res 2012; 32:2091–2095.

Back to Top | Article Outline

Anatomic and technical considerations for optimizing recovery of sexual function during robotic-assisted radical prostatectomy

Review: (pp. 88–94)

▪. Alemozaffar M, Duclos A, Hevelone ND, et al. Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. Eur Urol 2012; 61:1222–1228. [54]

▪. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205–1214. [04]

Badalato GM, Wosnitzer MS, Truesdale MD, Sandri M, et al. Evaluation of preoperative bioimpedance spectroscopy quantification of body composition on predicting postoperative outcomes following robotic assisted radical prostatectomy (RARP). Can J Urol 2011; 18:6031–6036.

Challacombe B. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons. BJU Int 2011; 108: 747–748.

Connolly SS, Cathcart PJ, Gilmore P, Kerger M, et al. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. BJU Int 2012; 109:752–759.

Dev H, Sharma NL, Dawson SN, Neal DE, et al. Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. BJU Int 2012; 109:1074–1080.

▪. Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012. [45]

▪. Ganzer R, Stolzenburg JU, Wieland WF, Brundl J. Anatomic study of periprostatic nerve distribution: immunohistochemical differentiation of parasympathetic and sympathetic nerve fibres. Eur Urol 2012; 62:1150–6. [42]

Gupta NP, Singh P, Nayyar R. Outcomes of robot-assisted radical prostatectomy in men with previous transurethral resection of prostate. BJU Int 2011; 108:1501–1505.

Hakimi AA, Faleck DM, Sobey S, Ioffe E, et al. Assessment of complication and functional outcome reporting in the minimally invasive prostatectomy literature from 2006 to the present. BJU Int 2012; 109:26–30.

Huang AC, Kowalczyk KJ, Hevelone ND, Lipsitz SR, et al. The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes. Eur Urol 2011; 59:595–603.

Hung CF, Yang CK, Cheng CL, Ou YC. Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. Anticancer Res 2011; 31:3497–3501.

Jung JH, Lee JW, Arkoncel FRP, Cho NH, et al. Significance of Perineural Invasion, Lymphovascular Invasion, and High-Grade Prostatic Intraepithelial Neoplasia in Robot-Assisted Laparoscopic Radical Prostatectomy. Ann Surg Oncol 2011; 18:3828–3832.

Kasraeian A, Barret E, Chan J, Sanchez-Salas R, et al. Comparison of the rate, location and size of positive surgical margins after laparoscopic and robot-assisted laparoscopic radical prostatectomy. BJU Int 2011; 108: 1174–1178.

Kim SC, Song C, Kim W, Kang T, et al. Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. Eur Urol 2011; 60:413–419.

Kim SC, Song C, Kim W, Kang T, et al. Reply from Authors re: Andrew Fuller, Stephen E. Pautler. Additional Evidence for Improved Functional Outcomes Following Robot-Assisted Radical Prostatectomy. Eur Urol 2011; 60:420–421Eur Urol 2011; 60:421–422.

Kimura M, Banez LL, Schroeck FR, Gerber L, et al. Factors Predicting Early and Late Phase Decline of Sexual Health-Related Quality of Life Following Radical Prostatectomy. J Sex Med 2011; 8:2935–2943.

Koie T, Yamamoto H, Hatakeyama S, Kudoh S, et al. Minimum incision endoscopic radical prostatectomy: Clinical and oncological outcomes at a single institute. Ejso 2011; 37:805–810.

▪. Kowalczyk KJ, Huang AC, Hevelone ND, et al. Stepwise Approach for Nerve Sparing Without Countertraction During Robot-Assisted Radical Prostatectomy: Technique and Outcomes. Eur Urol 2011; 60:536–547. [53]

Kowalczyk KJ, Huang AC, Hevelone ND, Lipsitz SR, et al. Stepwise Approach for Nerve Sparing Without Countertraction During Robot-Assisted Radical Prostatectomy: Technique and Outcomes. Eur Urol 2011; 60:536–547.

Labanaris AP, Witt JH, Zugor V. Robotic-assisted Radical Prostatectomy in Men >= 75 Years of Age. Surgical, Oncological and Functional Outcomes. Anticancer Res 2012; 32:2085–2089.

Labanaris AP, Zugor V, Witt JH. Robotic-assisted Radical Prostatectomy in Men <= 150 Years of Age. Surgical, Oncological and Functional Outcomes. Anticancer Res 2012; 32:2097–2101.

Louie-Johnsun M, Ouyang R, Indrajit B, Haque M. Laparoscopic radical prostatectomy: introduction of training during our first 50 cases. ANZ Journal of Surgery 2012; 82:131–135.

Madeb R, Golijanin D, Knopf JK, Kowalczyk J, et al. The Impact of Robotics on Treatment of Localized Prostate Cancer and Resident Education in Rochester, New York. J Endourol 2011; 25:573–577.

Magheli A, Gonzalgo ML, Su LM, Guzzo TJ, et al. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int 2011; 107:1956–1962.

McNicholas T. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons. BJU Int 2011; 108:747.

Meeks JJ, Eastham JA. Robotic Prostatectomy: The Rise of the Machines or Judgment Day. Eur Urol 2012; 61:686–687.

Mitchell RE, Clark PE, Scarpero HM. Assessing the Surgical Skills of Urology Residents After Preurology General Surgery Training: The Surgical Skills Learning Needs of New Urology Residents. J Surg Educ 2011; 68:341–346.

▪. Moore BM, Savdie R, Pe Benito RA, et al. The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. BJU Int 2012; 109:533–538. [17]

Mottrie A, Gallina A, De Wil P, Thuer D, et al. Balancing continence function and oncological outcomes during robot-assisted radical prostatectomy (RARP). BJU Int 2011; 108:999–1006.

Nilsson AE, Carlsson S, Johansson E, Jonsson MN, et al. Orgasm-Associated Urinary Incontinence and Sexual Life after Radical Prostatectomy. J Sex Med 2011; 8:2632–2639.

Nilsson AE, Schumacher MC, Johansson E, Carlsson S, et al. Age at surgery, educational level and long-term urinary incontinence after radical prostatectomy. BJU Int 2011; 108:1572–1577.

Novara G, Ficarra V, D'Elia C, Secco S, et al. Trifecta outcomes after robot-assisted laparoscopic radical prostatectomy. BJU Int 2011; 107:100–104.

▪. Novara G, Ficarra V, Rosen RC, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012; 62:431–452. [03]

Ou YC, Yang CR, Wang J, Cheng CL, et al. Learning Curve of Robotic-assisted Radical Prostatectomy With 60 Initial Cases by a Single Surgeon. Asian J Surg 2011; 34:74–80.

Ou YC, Yang CR, Wang J, Yang CK, et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int 2011; 108:420–425.

Patel V. Re: A Prospective, Non-Randomized Trial Comparing Robot-Assisted Laparoscopic and Retropubic Radical Prostatectomy in One European Institution. Eur Urol 2011; 60:599–600.

Patel VR, Coelho RF, Rocco B, Orvieto M, et al. Positive Surgical Margins After Robotic Assisted Radical Prostatectomy: A Multi-Institutional Study. J Urol 2011; 186:511–516.

Patel VR, Schatloff O, Chauhan S, Sivaraman A, et al. The Role of the Prostatic Vasculature as a Landmark for Nerve Sparing During Robot-Assisted Radical Prostatectomy. Eur Urol 2012; 61:571–576.

Patel VR, Sivaraman A, Coelho RF, Chauhan S, et al. Pentafecta: A New Concept for Reporting Outcomes of Robot-Assisted Laparoscopic Radical Prostatectomy. Eur Urol 2011; 59:702–707.

Peyromaure M. Re: Factors Determining Functional Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. Eur Urol 2012; 61:220–221.

Schatloff O, Chauhan S, Sivaraman A, Kameh D, et al. Anatomic Grading of Nerve Sparing During Robot-Assisted Radical Prostatectomy. Eur Urol 2012; 61:796–802.

Tewari A, Grover S, Sooriakumaran P, Srivastava A, et al. Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int 2012; 109:596–602.

Tewari AK, Shevchuk MM, Sterling J, Grover S, et al. Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery. BJU Int 2011; 108:1421–1429.

Touijer K. Positive surgical margin rate, location, and size following laparoscopic versus robotic-assisted laparoscopic radical prostatectomy. BJU Int 2011; 108: 1178–1179.

Walsh PC. Re: Stepwise Approach for Nerve Sparing Without Countertraction During Robot-Assisted Radical Prostatectomy: Technique and Outcomes Editorial Comment. J Urol 2012; 187:500.

Willis DL, Gonzalgo ML, Brotzman M, Feng ZY, et al. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012; 109:898–905.

Zugor V, Labanaris AP, Bauer RM, Witt JH. Surgical and Oncological Outcomes in Patients with a Preoperative PSA Value < 4 ng/ml Undergoing Robot-assisted Radical Prostatectomy. Anticancer Res 2012; 32:2079–2083.

Zugor V, Witt JH, Heidenreich A, Porres D, et al. Surgical and Oncological Outcomes in Patients with Preoperative PSA > 20 ng/ml Undergoing Robot-assisted Radical Prostatectomy. Anticancer Res 2012; 32:2091–2095.

© 2013 Lippincott Williams & Wilkins, Inc.